MannKind (MNKD) Stock Forecast & Price Target

MannKind is well positioned for a positive re-rating because its business is diversifying beyond Tyvaso DPI into a faster-growing, more controllable commercial base led by Furoscix, Afrezza, and MNKD-201. Furoscix’s ReadyFlow launch converted ~90% of new prescriptions in the first three weeks, Afrezza’s pediatric launch surpassed its adult market share within 90 days after the May 29, 2026 approval, and management indicated the company could become profitable and does not need to raise capital. Financially, the setup is supported by modeled 2026 net sales of $95M for Furoscix and $76.9M for Afrezza, while the balance sheet shows ~$422M of debt against ~$111M of cash at 2Q26, making execution on these launches the key determinant of upside.

MannKind is viewed negatively because its valuation depends heavily on Tyvaso DPI, which remains the largest revenue contributor at about $128M in 2025 and only generates a 10% royalty on UTHR sales, leaving it exposed to partner-controlled economics and TreSMI-related competitive headwinds. Its diversification efforts look fragile: Furoscix has only about 3 years of sales and 2026E is below management’s $110M–$120M target, while Afrezza’s pediatric launch is early and faces payer, eligibility, and entrenched competitor risks. The highest-risk catalyst, MNKD-201, has unproven inhaled efficacy, small short-duration data, and only a 25% probability of success, so any setback could erase roughly $109M of probability-adjusted 2035 revenue.